Brazil’s state-run Oswaldo Cruz Foundation (Fiocruz) has developed two types of polymerase chain reaction (PCR) tests to detect the monkeypox virus, a disease that has left more than 2,000 cases in the South American country, the institution announced today.
Fiocruz applied to the National Health regulator (Anvisa) for registration of the two molecular tests to detect the disease.
One PCR test allows the identification of viral DNA in samples of skin rashes present in the person with a suspected infection.
The other is used for differential diagnosis, ruling out other possibilities of diagnosis by related viruses.
Two protocols can be used in testing: The first, the MPXV test, involves the detection and typing of monkeypox. In the case of a negative test, the second protocol increases the possibility of clarifying the diagnosis using the differential test.
According to Fiocruz, this is important for epidemiological surveillance in the Unified Health System (SUS).
Fiocruz has not only developed tests and applied for their approval but has already produced a sufficient quantity of tests for 12,000 suspected cases and claims to be able to increase production of these kits without affecting the supply of other products in its portfolio.
Fiocruz President Nísia Trindade Lima said that a more efficient supply chain and a strengthened local production system contribute to national autonomy regarding key inputs to address public health issues.
Brazil is the Latin American country most affected by monkeypox. According to the latest data from the Ministry of Health, there are at least 2,131 confirmed cases in Brazil, with another 1,896 currently being tested. In addition, the disease has caused one death.